SI2663564T1 - Spojina imidazo(4,5-c)kinolin-2-on in uporaba le-te kot dvojnega inhibitorja pi3 kinaze / mtor - Google Patents
Spojina imidazo(4,5-c)kinolin-2-on in uporaba le-te kot dvojnega inhibitorja pi3 kinaze / mtorInfo
- Publication number
- SI2663564T1 SI2663564T1 SI201230117T SI201230117T SI2663564T1 SI 2663564 T1 SI2663564 T1 SI 2663564T1 SI 201230117 T SI201230117 T SI 201230117T SI 201230117 T SI201230117 T SI 201230117T SI 2663564 T1 SI2663564 T1 SI 2663564T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazoš4
- cćquinolin
- kinase
- compound
- dual inhibitor
- Prior art date
Links
- 101150097381 Mtor gene Proteins 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940125436 dual inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161432958P | 2011-01-14 | 2011-01-14 | |
| PCT/US2012/020897 WO2012097039A1 (en) | 2011-01-14 | 2012-01-11 | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor |
| EP12701207.8A EP2663564B1 (en) | 2011-01-14 | 2012-01-11 | Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2663564T1 true SI2663564T1 (sl) | 2015-01-30 |
Family
ID=45531593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201230117T SI2663564T1 (sl) | 2011-01-14 | 2012-01-11 | Spojina imidazo(4,5-c)kinolin-2-on in uporaba le-te kot dvojnega inhibitorja pi3 kinaze / mtor |
Country Status (39)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015073804A2 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of blocking transmission of malarial parasite |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| HK1254687A1 (zh) | 2015-12-15 | 2019-07-26 | Eli Lilly And Company | 用於癌症的联合疗法 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN109310684B (zh) | 2016-04-12 | 2021-11-19 | 伊莱利利公司 | 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法 |
| US11564929B2 (en) * | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| CA3025024A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| WO2018017410A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
| WO2018063873A1 (en) | 2016-09-27 | 2018-04-05 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| RS65761B1 (sr) | 2018-06-15 | 2024-08-30 | Janssen Pharmaceutica Nv | Analozi rapamicina i njihova upotreba |
| WO2020081329A1 (en) * | 2018-10-18 | 2020-04-23 | Camp4 Therapeutics Corporation | Methods and compositions for modulating pcsk9 and angptl3 expression |
| KR20220128345A (ko) | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
| CA3184212C (en) * | 2020-09-21 | 2024-11-05 | Wei Zhong | 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLEIN-2-ONE SUBSTITUTE COMPOUNDS WITH THE ABILITY TO CROSS THE BLOOD-BRAIN BARRIER |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| EP4453211A1 (en) | 2021-12-22 | 2024-10-30 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| WO2005054237A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| AU2006216798A1 (en) * | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
| WO2007106854A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
| ES2614130T3 (es) | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
| CN102803259A (zh) | 2009-06-04 | 2012-11-28 | 诺瓦提斯公司 | 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物 |
| EP2438064A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
| WO2011001212A1 (en) * | 2009-06-30 | 2011-01-06 | Piramal Life Sciences Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| KR20140014104A (ko) * | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
-
2011
- 2011-12-20 JO JOP/2011/0389A patent/JO3003B1/ar active
- 2011-12-22 AR ARP110104894A patent/AR084551A1/es unknown
- 2011-12-23 TW TW100148428A patent/TWI518086B/zh not_active IP Right Cessation
-
2012
- 2012-01-11 US US13/347,886 patent/US8440829B2/en not_active Expired - Fee Related
- 2012-01-11 SG SG2013047311A patent/SG191744A1/en unknown
- 2012-01-11 MX MX2013008185A patent/MX2013008185A/es active IP Right Grant
- 2012-01-11 WO PCT/US2012/020897 patent/WO2012097039A1/en not_active Ceased
- 2012-01-11 CA CA2824760A patent/CA2824760C/en not_active Expired - Fee Related
- 2012-01-11 MY MYPI2013701219A patent/MY164705A/en unknown
- 2012-01-11 EA EA201390823A patent/EA022163B1/ru not_active IP Right Cessation
- 2012-01-11 PL PL12701207T patent/PL2663564T3/pl unknown
- 2012-01-11 RS RS20150095A patent/RS53828B1/sr unknown
- 2012-01-11 PE PE2013001553A patent/PE20140864A1/es active IP Right Grant
- 2012-01-11 HR HRP20150135AT patent/HRP20150135T1/hr unknown
- 2012-01-11 PH PH1/2013/501493A patent/PH12013501493A1/en unknown
- 2012-01-11 ME MEP-2015-14A patent/ME02019B/me unknown
- 2012-01-11 BR BR112013017672A patent/BR112013017672A2/pt not_active Application Discontinuation
- 2012-01-11 KR KR1020137018235A patent/KR101561360B1/ko not_active Expired - Fee Related
- 2012-01-11 DK DK12701207.8T patent/DK2663564T3/en active
- 2012-01-11 HU HUE12701207A patent/HUE024426T2/en unknown
- 2012-01-11 PT PT127012078T patent/PT2663564E/pt unknown
- 2012-01-11 JP JP2013549509A patent/JP5891247B2/ja not_active Expired - Fee Related
- 2012-01-11 AU AU2012205619A patent/AU2012205619B2/en not_active Ceased
- 2012-01-11 ES ES12701207.8T patent/ES2531891T3/es active Active
- 2012-01-11 EP EP12701207.8A patent/EP2663564B1/en active Active
- 2012-01-11 SI SI201230117T patent/SI2663564T1/sl unknown
- 2012-01-11 CN CN201280005256.0A patent/CN103282364B/zh not_active Expired - Fee Related
- 2012-11-01 UA UAA201308519A patent/UA109921C2/ru unknown
-
2013
- 2013-04-16 US US13/863,411 patent/US8658668B2/en not_active Expired - Fee Related
- 2013-06-03 TN TNP2013000237A patent/TN2013000237A1/fr unknown
- 2013-06-14 CR CR20130289A patent/CR20130289A/es unknown
- 2013-06-24 IL IL227165A patent/IL227165A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04757A patent/ZA201304757B/en unknown
- 2013-07-01 DO DO2013000158A patent/DOP2013000158A/es unknown
- 2013-07-09 CL CL2013002005A patent/CL2013002005A1/es unknown
- 2013-07-11 GT GT201300180A patent/GT201300180A/es unknown
- 2013-07-12 EC ECSP13012764 patent/ECSP13012764A/es unknown
- 2013-07-12 SV SV2013004496A patent/SV2013004496A/es unknown
- 2013-07-25 CO CO13176485A patent/CO6731133A2/es unknown
-
2015
- 2015-01-30 CY CY20151100096T patent/CY1116007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2663564T1 (sl) | Spojina imidazo(4,5-c)kinolin-2-on in uporaba le-te kot dvojnega inhibitorja pi3 kinaze / mtor | |
| EP2683243A4 (en) | PI3 KINASE INHIBITORS AND USES THEREOF | |
| ZA201309128B (en) | Macrocyclic compounds as protein kinase inhibitors | |
| ZA201402561B (en) | Benzonitrile derivatives as kinase inhibitors | |
| PL2710007T3 (pl) | Inhibitory kinazy | |
| ZA201404156B (en) | Kinase inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| PT2624696T (pt) | Derivados de benzimidazole como inibidores da cinase pi3 | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| IL229028A0 (en) | Kinase inhibitors | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| AP3597A (en) | Imidazopyridazines as akt kinase inhibitors | |
| SG11201404522VA (en) | Crystalline pi3 kinase inhibitors | |
| EP2571884A4 (en) | SELECTIVE MTOR KINASE HEMMER | |
| ZA201404157B (en) | Kinase inhibitors |